Larimar Therapeutics Inc. Common Stock (LRMR)
Stock · NASDAQ · Health Care
$4.01as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$3.58
Industry
Biotechnology: Pharmaceutical Preparations
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 71
- Website
- larimartx.com/
Fundamentals
- 1-day range
- $3.98$4.08
- Market cap
- $413.45M
- P/E (trailing)
- —
- P/E (forward)
- -3.78
- EPS (trailing)
- $-1.99
- Dividend yield
- —
- Beta
- 0.69
- Avg. volume
- 1.97M
- Dividend pay date
- May 29, 2020
52-week range
$2.72$6.42
Next earnings: November 5, 2026 · EPS estimate $-0.35After Closeconfirmed
Forecasts
10 analyst ratings
Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$26
+548.4%
Median
$12.5
+211.7%
Low
$5
+24.7%
Larimar Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LRMRLarimar Therapeutics Inc. Common Stock$4▼ 1.23%Market cap $413.45MP/E —$2.72$6.42
- KMDAKamada Ltd. Ordinary Shares$8.29▲ 0.36%Market cap $417.07MP/E 20.65$6.5$9.35
- BNTCBenitec Biopharma Inc. Common Stock$12.51▼ 1.30%Market cap $417.41MP/E —$9.85$16.76
- EOLSEvolus Inc. Common Stock$8.89▲ 0.06%Market cap $398.42MP/E —$3.86$9.12
- PBYIPuma Biotechnology Inc Common Stock$9.07▼ 1.89%Market cap $391.42MP/E 18.65$4.3$9.51
- PRTAProthena Corporation plc Ordinary Shares$9.35▲ 2.86%Market cap $436.10MP/E —$7.73$11.8
- SGMTSagimet Biosciences Inc. Series A Common Stock$10.55▼ 1.86%Market cap $441.53MP/E —$4.5$11.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LRMR Larimar Therapeutics Inc. Common Stock | $413.45M | — | $4 | ▼ 1.23% | $2.72$6.42 |
| KMDA Kamada Ltd. Ordinary Shares | $417.07M | 20.65 | $8.29 | ▲ 0.36% | $6.5$9.35 |
| BNTC Benitec Biopharma Inc. Common Stock | $417.41M | — | $12.51 | ▼ 1.30% | $9.85$16.76 |
| EOLS Evolus Inc. Common Stock | $398.42M | — | $8.89 | ▲ 0.06% | $3.86$9.12 |
| PBYI Puma Biotechnology Inc Common Stock | $391.42M | 18.65 | $9.07 | ▼ 1.89% | $4.3$9.51 |
| PRTA Prothena Corporation plc Ordinary Shares | $436.10M | — | $9.35 | ▲ 2.86% | $7.73$11.8 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $441.53M | — | $10.55 | ▼ 1.86% | $4.5$11.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11Benzinga · 8/5/2026
- Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) EstimateBenzinga · 8/4/2026
Insider Activity
Insider Actions →Acquired
380.9K
Disposed
0
- Hamilton Thomas Edward · July 6, 2026 · Buy50.0K @ $3.34
- Truitt Joseph · May 19, 2026 · Grant55.1K
- Hamilton Thomas Edward · May 19, 2026 · Grant55.1K
- THOMAS FRANK E · May 19, 2026 · Grant55.1K
- SHERMAN JEFFREY W · May 19, 2026 · Grant55.1K
- LEFF JONATHAN S · May 19, 2026 · Grant55.1K
- DEERFIELD MANAGEMENT COMPANY, L.P. · May 19, 2026 · Grant55.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 87.44M
- Total value held
- $392.22M
- Institutional holders
- 157
Top holders this quarter
- Unknown35.61M
- Unknown7.12M
- Unknown3.75M
- Unknown3.63M
- Unknown3.00M
- Unknown2.93M
- Unknown2.87M
- Unknown2.03M
- Unknown1.65M
- Unknown1.50M
See the full, filterable feed with live charts on the MarketWall dashboard.